General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novartis(SIGNIFICANT), NovoNordisk(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Elixir Medical(MODEST), Stel(MODEST) OWNERSHIP/PARTNERSHIP/PRINCIPAL: CONTROLRAD(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Beth Israel Deaconess Medical Center(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Concept Medical(SIGNIFICANT), Chiesi(SIGNIFICANT), Boston Scientific(SIGNIFICANT), Idorsia Pharmaceuticals(MODEST), Janssen(SIGNIFICANT), Alleviant Medical(SIGNIFICANT), Amgen Inc.(MODEST), RM Global(MODEST), Medtelligence(MODEST), Faraday Pharmaceuticals(SIGNIFICANT), Duke University(MODEST), Mediasphere(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), Affluent Medical(MODEST), MedAlliance(MODEST), MedScape(MODEST), Medtronic(SIGNIFICANT), CERC(SIGNIFICANT), Sanofi(MODEST)

View Full Disclosure